Clinical Trials Logo

Glaucoma, Primary Open Angle clinical trials

View clinical trials related to Glaucoma, Primary Open Angle.

Filter by:

NCT ID: NCT01814761 Completed - Ocular Hypertension Clinical Trials

A Study of Bimatoprost 0.01% in the Clinical Setting

APPEAL-Taiwan
Start date: May 2013
Phase: Phase 4
Study type: Observational

This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).

NCT ID: NCT01737853 Completed - Clinical trials for Glaucoma Primary Open Angle

Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Start date: February 2011
Phase: N/A
Study type: Observational

The objective of this phase IV clinical multi-center trial will be to compare the efficacy and safety of Ganforti® versus Krytantek®, using a cross-over design during a six month period (including a one-month wash-in period) in POAG and OH patients.

NCT ID: NCT01408472 Completed - Clinical trials for Glaucoma, Primary Open Angle

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

Start date: April 2011
Phase: Phase 1
Study type: Interventional

Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in glaucoma. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.